Department of Internal Medicine

Hematology, Oncology and Blood &  Marrow Transplantation Faculty

Brian Link photo

Medical School:
The University of Iowa

Residency:
Rush Presbyterian St. Luke's Hospital, Chicago

Fellowship:
The University of Iowa

Brian K. Link, M.D.
Professor
Interim Director of Clinical Services, Division of Hematology, Oncology and Blood & Marrow Transplantation

Dr. Link's clinical and research interests focus on the immunotherapy of lymphoid malignancies. He is the principal investigator on a number of protocols utilizing monoclonal antibodies and other immunomodulators for use in the therapy of human lymphoid malignancies.

Honors, Awards, and Organizations

Recent Publications

  1. Lubaroff, D.M., Konety, B., Link, B.K., Ratliff, T.L., Madsen, T., Shannon, M., Ecklund, D., Williams, R.D. Clinical protocol: phase I study of an denovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Hum Gene Ther. 2006 Feb; 17 (2):220-9.
  2. Chand, V.K., Link, B.K., Ritchie, J.M., Shannon, M., Wooldridge, J.E. Neutropenia and febrile neutropenia in patients with Hodgkin’s lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leukemia and Lymphoma, 2006 Apr; 47 (4):657-663.
  3. Chen-Hardee, S., Chrischilles, E.A., Voelker, M.D., Brooks, J.M., Scott, S., Link, B.K., Delgado, D. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin’s lymphoma (United States). Cancer Causes Control, 2006 Jun; 17 (5):647-54.
  4. Link, B.K., Ballas, Z.K., Weisdorf, D., Wooldridge, J.E., Bossler, A.D., Shannon, M., Rasmussen, W.L., Krieg, A.M., Weiner, G.J. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immulologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother, 2006 Sep-Oct; 29 (5):558-68.
  5. Bowles, J.A., Wang, S.Y., Link, B.K., Allan, B., Beuerlein, G., Campbell, M.A., Marquis, D., Ondek, B., Wooldridge, J.E., Smith, B.J., Breitmeyer, J.B., Weiner, G.J. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood, 2006 Oct 15; 108 (8):2648-54.
  6. Leonard, J.P., Link, B.K., Emmanouilides, C., Gregory, S.A., Weisdorf, D.A., Andrey, J., John Hainsworth, Sparano, J.A., Tsai, D.E., Horning, S., Krieg, A.M., Weiner, G.J. Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 (CpG 7909) With and Following Rituximab in Patients With Recurrent Indolent and Aggressive Non-Hodgkin’s Lymphoma Clinical Cancer Research, 2007 Oct. 13:6168-6174.
  7. A. Hagenbeek, T. Plesner, P. Johnson, L. Pedersen, J. Walewski, A. Hellmann, B.K. Link, M. Wojtukiewicz, M. Pfreundschuh, M. Kneba, A. Engert, P. Sonneveld, J.A. Radford, M. Flensburg, J. Petersen, N. Losic, T. Robak. First human exposure of Ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase I/II trial BLOOD, 2008 Jun: 111:5486-5495.
  8. Byrd, J.C., Shinn, C.A., Pearson, M.D., Flinn, I.W., Link, B.K., Wang, H., Weiner, G., Grover, M.R.: Hu IDI0 induces apototosis in vitro in human chronic lymphocytic leukemia cells (CLL) independent of compliant mediated lysis but requires Fcj receptor ligation. Blood (in press 2001).
  9. Davis, T., Grillo-Lopez, A., White, C., McLaughlin, P., Czuczman, M., Link, B., Maloney, D., Weaver, R., Rosenberg, J., and Levy, R. Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Retreatment. J Clin Oncol. 18:3135-3143, 2000.
  10. Warren, T.W., Shannon, M., Link, B.K., A phase I Study of CPG 7909 in Patients with Previously Treated Non Hodgkin's Lymphoma. Clinical Lymphoma (In Press, 2001).
  11. Vose, J.M., Link, B.K., Grossbard, M., Fisher, R.I., Czuczman, M., Gilman, P., Lowe, A.M,.: Phase II Pilot Study of the Safety and Efficacy of Rituximab in combination with CHOP Chemotherapy in Patients with Previously Untreated Intermediate or High-Grade NHL. J Clin Oncol 2001 19: 389-397.
  12. Buban, G., Link, B.K., Doucette, W. Influences on Oncologists' Adoption of New Agents in Adjuvant Chemotherapy of Breast Cancer J. Clin Ocol. 2001 19: 954-959.
  13. Jahrsdörfer, B., Hartmann, G., Racila, E., Jackson, W., Mühlenhoff, L., Meinhardt, G., Endres, S., Link, B.K., Krieg, A.M., Weiner, G.J.: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukocyte Biol . 2001.
  14. Treon, S., Agus, D.B., Link, B.K., Rodrigues, G., Molina, A., Lacy, M.Q., Fisher, D.C., Emmanouilides, C., Richards, A., Clark, B., Lucas, M.S., Schlossman, R., Anderson, K.C., and Byrd, J.C.: A Retrospective Study on the Activity of Rituximab in Patients with Waldenstrom's Macroglobulinemia. Journal of Immunotherapy, June 2001.
  15. Link, B.K., Budd, T.G., Scott, S., Dickman, E., Paul, D., Lawless, G., Lee, M., Fridman, M., Ford, J., and Carter, W.B. Delivering Adjuvant Chemotherapy to Women with Early-Stage Breast Cancer: Current Patterns of Care. In Press Cancer 2001.
  16. Sheri A. Kostelny, Brian K. Link, J. Yun Tso, Max Vasquez, Brett H. Jorgensen, Hong Wang, William C. Hall, and George J. Weiner. Humanization and Characterization of the Anti-HLA-DR Antibody 1D10 In Press Int J Can 2001.

Links of Interest

Back to Hematology-Oncology Faculty List